Skip to contentO
Oncotelic Therapeutics, Inc.
O
OTLCOncotelic Therapeutics, Inc. Q4 2015 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net income—
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$3,978,000N/M Operating Cash Flowderived
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oncotelic Therapeutics, Inc. · CIK 908259 · Engraved from SEC EDGAR
Free Cash Flowderived-$2,965,000— ended Dec 31, 2015 · filed Mar 25, 2016 · 85 d after period end